BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1147
- Registration Number
- NCT04008030
- Locations
- 🇩🇪
Local Institution - 0117, Hamburg, Germany
🇩🇪Local Institution - 0008, Hannover, Germany
🇩🇪Local Institution - 0009, Heidelberg, Germany
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 219
- Registration Number
- NCT03994601
- Locations
- 🇺🇸
Local Institution - 0075, Costa Mesa, California, United States
🇺🇸Local Institution - 0050, Orange, California, United States
🇪🇸Local Institution - 0024, Majadahonda, Spain
A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT03981094
- Locations
- 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States
A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 261
- Registration Number
- NCT03980314
- Locations
- 🇺🇸
Local Institution - 0043, Pittsburgh, Pennsylvania, United States
🇧🇷Local Institution - 0039, Barretos, Sao Paulo, Brazil
🇧🇷Local Institution - 0041, Rio de Janeiro, Brazil
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT03978611
- Locations
- 🇺🇸
Local Institution - 0002, Los Angeles, California, United States
🇧🇪Local Institution - 0018, Bruxelles, Brussels, Belgium
🇧🇪Local Institution - 0016, Brussels, Belgium
A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 21
- Registration Number
- NCT03979248
- Locations
- 🇳🇱
PRA Health Sciences - Netherlands, Groningen, Netherlands
Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects
- Conditions
- Autoimmune Diseases
- Interventions
- Drug: BMS-986165Other: Placebo
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 135
- Registration Number
- NCT03956953
- Locations
- 🇨🇳
Local Institution, Beijing, Beijing, China
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
- Conditions
- Advanced Solid Cancers
- Interventions
- Drug: BMS-986301Biological: NivolumabBiological: Ipilimumab
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 54
- Registration Number
- NCT03956680
- Locations
- 🇺🇸
Local Institution - 0003, Chicago, Illinois, United States
🇺🇸Local Institution - 0002, Nashville, Tennessee, United States
🇺🇸Local Institution - 0005, Saint Louis, Missouri, United States
A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT03950960
- Locations
- 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States
An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT03943147
- Locations
- 🇺🇸
The Regents of The University of California, Los Angeles, California, United States
🇺🇸NewYork-Presbyterian Queens, Fresh Meadows, New York, United States
🇺🇸Northwell Health Physician Partners at Great Neck, Great Neck, New York, United States